(Q46621426)

23 December 2017

title

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype (English)

1 reference

23 December 2017

1 reference

1 reference

J S Marinac

1

1 reference

23 December 2017

J D Balian

2

1 reference

23 December 2017

J W Foxworth

3

1 reference

23 December 2017

S K Willsie

4

1 reference

23 December 2017

J C Daus

5

1 reference

23 December 2017

R Owen

6

1 reference

23 December 2017

D A Flockhart

7

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 1996

1 reference

23 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

23 December 2017

volume

60

1 reference

23 December 2017

page(s)

138-144

1 reference

23 December 2017

issue

2

1 reference

23 December 2017

Genetic differences in drug disposition

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

21 January 2018

Gerontokinetics--a reply

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Clinical consequences of polymorphic drug oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Polymorphic hydroxylation of Debrisoquine in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Genetically determined debrisoquine oxidation capacity in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Genetic polymorphism of S-mephenytoin hydroxylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Determination of omeprazole and metabolites in plasma and urine by liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Omeprazole therapy in resistant reflux disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990129-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0009-9236(96)90129-0

1 reference

23 December 2017

PubMed ID

8823231

1 reference

23 December 2017